Immune Resilience

This protocol is for IMMUNE RESILIENCE — building robustness over months, not treating acute illness. If you currently have a cold, flu, COVID, or any other active infection, this is the wrong tool right now. Peptides do not replace antivirals, antibiotics, antifungals, or the standard medical treatment of infection. Resilience work is what you do BEFORE you need it.

The protocol assumes you are a healthy adult interested in supporting immune function over a multi-month timescale — typically users approaching cold-and-flu season, recovering from chronic-inflammation states, or wanting to support recovery from a prolonged stressor. It is NOT for users with autoimmune disease (where additional immune modulation cuts against the immunosuppressive treatments those conditions usually require), active cancer treatment, or active infectious disease.

If you have an autoimmune diagnosis, recent cancer history, or active infection, the answer is your physician, not this protocol.

Phases

1. Phase 1 — Foundation (TA-1 cycle + glutathione substrate)

   8-12 weeks per cycle, 2-4 cycles/year

   Thymosin Alpha-1 (TA-1) at 1.6mg SubQ twice weekly during the cycle — same dose used clinically as Zadaxin for hepatitis B. Layer in glutathione 200mg SubQ 2x/week as the antioxidant substrate that supports the immune-modulation effects. Phase 1 is the editorial baseline — most users won't need Phase 2 if they cycle this consistently.

   • Thymosin Alpha-11.60 mg · twice weekly · morning

     1.6mg SubQ twice weekly during the cycle (e.g., Monday + Thursday). Matches the Zadaxin clinical dose. Most community users run 8-12 week cycles, 2-4 times per year, often timing one cycle for cold-and-flu season.

   • Glutathione200 mg · twice weekly · morning

     200mg SubQ twice weekly (can co-administer with TA-1 — different injection sites). Antioxidant substrate supporting the immune-modulation work. Oral glutathione has poor bioavailability; SubQ or IV is the effective route.

   What “working” looks like

   Fewer / shorter respiratory infections over a cold-and-flu season cycle. Faster recovery when you do get sick (this protocol won't prevent every infection — what changes is the duration and severity). Better recovery from training stress. No subjective acute signal during a cycle — the benefit emerges across months.

   Decision criteria

   Complete the 8-12 week cycle, then pause 4-8 weeks before considering Phase 2 or scheduling the next cycle. The strongest editorial pattern is 2-4 cycles per year (e.g., one fall cycle + one spring cycle). If after 2 full cycles you see no benefit: this protocol isn't working in your physiology; discontinue.

   Labs to pull

   • CBC + differential (baseline immune-cell counts)
   • Quantitative immunoglobulins (IgG, IgA, IgM) if you have unexplained recurrent infections — establishes whether the issue is humoral immunity
   • hs-CRP + ESR (chronic inflammation baseline)

2. Phase 2 — Antimicrobial + anti-inflammatory layer (optional)

   8-12 weeks per cycle, alongside Phase 1

   OPTIONAL. Add LL-37 (antimicrobial peptide, broad-spectrum mechanism against bacteria/viruses/fungi) for users with chronic infectious-burden patterns. Add KPV (anti-inflammatory tripeptide from α-MSH) for users with mucosal-inflammatory or inflammatory-skin presentations. Both are Tier 3; mechanism is real, human-outcome evidence is thin. Continue Phase 1 throughout.

   • Thymosin Alpha-11.60 mg · twice weekly · morning

     Continue Phase 1 dose. The Phase 1 foundation is the maintenance base; Phase 2 layers on for users who need more.

   • Glutathione200 mg · twice weekly · morning

     Continue Phase 1 substrate dose.

   • LL-37250 mcg · daily · evening

     250mcg SubQ daily during the cycle. Antimicrobial peptide with broad-spectrum mechanism. Mast cell degranulation in atopic users is the most common adverse signal — see Caution #5.

   • KPV500 mcg · daily · evening

     500mcg SubQ daily during the cycle. Anti-inflammatory tripeptide — particularly useful for mucosal inflammation (gut, sinus) or inflammatory skin patterns layered with the immune work.

   What “working” looks like

   Reduced chronic-inflammation symptoms (joint stiffness on waking, persistent low-grade fatigue, sinus / gut inflammation if those are presenting). Phase 2 effects often emerge faster than Phase 1 because LL-37 + KPV act on different mechanism layers (acute antimicrobial vs anti-inflammatory).

   Decision criteria

   After first 8-12 week Phase 2 cycle: pause for 4-8 weeks. If Phase 1+2 combined delivered meaningful improvement vs Phase 1 alone, schedule a second cycle. If no clear delta: discontinue Phase 2 and return to Phase 1 maintenance — the cost + injection burden isn't justified.

Often combined with

• Recovery from Injury

  Phase 1 anti-inflammatory + immune-modulation effects support tissue repair when running concurrently with Recovery from Injury. No peptide conflicts — TA-1 + glutathione + the BPC/TB pairing work on different mechanism layers.

• Longevity

  Glutathione overlaps with the longevity substrate work (oxidative stress reduction). If running both protocols, do NOT double-dose glutathione — pick the protocol's dosing schedule that came first and treat it as primary.

• Energy & Vitality

  Chronic low-grade inflammation is a quiet drain on cognitive + physical energy. Users running the Energy protocol whose mitochondrial layer (Phase 2 SS-31) only partially works often benefit from layering Immune Resilience Phase 1 — addresses an upstream inflammatory cause rather than the downstream energy symptom.